Abstract
Bisphosphonates are strong inhibitors of osteoclastic bone resorption in both benign and malignant bone diseases. The nitrogen-containing bisphosphonates (N-BPs) have strong cytotoxicity via inhibition of protein prenylation in the mevalonate pathway, and also demonstrate direct cytostatic and proapoptotic effects on prostate cancer cells. We confirmed the usefulness of a co-culture system comprised of prostatic LNCaP cells, ST2 cells (mouse-derived osteoblasts) and MLC-6 cells (mouse-derived osteoclasts) in vitro. N-BPs (pamidronate and zoledronic acid) inhibited both androgen receptor transactivation and tumor cell proliferation by suppressing the activities of both osteoclasts and osteoblasts with low-dose exposure. This indirect inhibition of prostate cancer cells via bone cells could be beneficial in treating prostate cancer patients with bone metastases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Bone Density Conservation Agents / pharmacology
-
Cell Proliferation / drug effects
-
Coculture Techniques
-
Diphosphonates / pharmacology*
-
Humans
-
Imidazoles / pharmacology*
-
Luciferases / metabolism
-
Male
-
Mice
-
Osteoblasts / cytology
-
Osteoclasts / cytology
-
Pamidronate
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Receptors, Androgen / genetics
-
Receptors, Androgen / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Transcriptional Activation
-
Tumor Cells, Cultured
-
Zoledronic Acid
Substances
-
Antineoplastic Agents
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
RNA, Messenger
-
Receptors, Androgen
-
Zoledronic Acid
-
Luciferases
-
Pamidronate